thymoquinone has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebrahimi, SS; Hassanzadeh, K; Izadpanah, E; Oryan, S | 1 |
| Ardah, MT; Haque, ME; Merghani, MM | 1 |
2 other study(ies) available for thymoquinone and Parkinsonian Disorders
| Article | Year |
|---|---|
Thymoquinone exerts neuroprotective effect in animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Basal Ganglia; Behavior, Animal; Benzoquinones; Cytoprotection; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dynamins; Male; Motor Activity; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Rotenone; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases | 2017 |
Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates α-synuclein aggregation in vitro.
Topics: alpha-Synuclein; Animals; Benzoquinones; Cell Line, Tumor; Corpus Striatum; Humans; Male; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Parkinsonian Disorders; Protein Aggregates | 2019 |